​Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder counting for 60-70% of dementia cases worldwide. Despite decades of research, the understanding of AD pathogenesis is limited which challenges the development of novel therapies for AD treatment. Considering the existing dilemma in the diagnosis and treatment of AD, the identification of a wide range of candidate biomarkers is necessary. MicroRNA (miRNA)  can influence pathological processes associated with AD and might serve as potential disease biomarkers. Nevertheless, the mechanisms through which miRNAs engage in ADs pathology are still being investigated. Moreover, using miRNA alone for AD diagnosis faces challenges related to specificity and accuracy. Given that AD is a multifactorial complex disease with dynamic nature, integrating multiple types of biomarkers will enhance the diagnosis and the understanding of the molecular mechanisms behind AD by capturing the dynamic changes of the disease more accurately. In the current research the mechanisms through which miR-RNA  are engaged in ADs pathology will be investigated at the molecular level using integrated omics approach; proteomics and metabolomics using cell models for AD. Using integrated approach will enhance the diagnostic accuracy of AD, provide a holistic view and deeper insights into AD’s pathogenesis, and facilitate the discovery of new therapeutic targets for drug development​​

The Project is Funded by Abdul Hameed Shoman Foundation​ (JD 15000)​